Department of Obstetrics, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Department of Obstetrics and Gynecology, People's Hospital Affiliated to Shandong First Medical University, Jinan, China.
BMC Womens Health. 2024 Apr 1;24(1):208. doi: 10.1186/s12905-024-03049-4.
Placenta accreta spectrum disorder (PAS) is a serious obstetric complication associated with significant maternal morbidity and mortality. Prophylactic balloon occlusion (PBO), as an intravascular interventional therapies, has emerged as a potential management strategy for controlling massive hemorrhage in patients with PAS. However, current evidence about the clinical application of PBO in PAS patients are still controversial. This study aimed to evaluate the effectiveness and safety of PBO in the management of PAS.
A retrospective cohort study including PAS patients underwent cesarean delivery was conducted in a tertiary hospital from January 2015 to March 2022. Included PAS patients were further divided into balloon and control groups by whether PBO was performed. Groups were compared for demographic characteristics, intraoperative and postoperative parameters, maternal and neonatal outcomes, PBO-related complication and follow up outcomes. Additionally, multivariate-logistic regression analysis was performed to determine the definitive associations between PBO and risk of massive hemorrhage and hysterectomy.
A total of 285 PAS patients met the inclusion criteria were included, of which 57 PAS patients underwent PBO (PBO group) and 228 women performed cesarean section (CS) without PBO (control group). Irrespective of the differences of baseline characteristics between the two groups, PBO intervention did not reduce the blood loss, hysterectomy rate and postoperative hospital stay, but it prolonged the operation time and increased the cost of hospitalization (All P < 0.05) Additionally, there were no significant differences in postoperative complications, neonatal outcomes, and follow-up outcomes(All P > 0.05). In particular, patients undergoing PBO were more likely to develop the venous thrombosis postoperatively (P = 0.001). However, multivariate logistic regression analysis showed that PBO significantly decreased the risk of massive hemorrhage (OR 0.289, 95%CI:0.109-0.766, P = 0.013). The grade of PAS and MRI with S2 invasion were the significant risk factors affecting massive hemorrhage(OR:6.232 and OR:5.380, P<0.001).
PBO has the potential to reduce massive hemorrhage in PAS patients undergoing CS. Obstetricians should, however, be aware of potential complications arising from the PBO. Additionally, MRI with S2 invasion and PAS grade will be useful to identify PAS patients who at high risk and may benefit from PBO. In brief, PBO seem to be a promising alternative for management of PAS, yet well-designed randomized controlled trials are needed to convincingly demonstrate its benefits and triage the necessity of PBO.
胎盘植入谱系疾病(PAS)是一种严重的产科并发症,与产妇发病率和死亡率显著相关。预防性球囊阻断(PBO)作为一种血管内介入治疗方法,已成为控制 PAS 患者大出血的潜在治疗策略。然而,目前关于 PAS 患者中 PBO 的临床应用的证据仍然存在争议。本研究旨在评估 PBO 在 PAS 管理中的有效性和安全性。
对 2015 年 1 月至 2022 年 3 月在一家三级医院接受剖宫产分娩的 PAS 患者进行了回顾性队列研究。纳入的 PAS 患者根据是否进行 PBO 进一步分为球囊组和对照组。比较两组患者的人口统计学特征、术中及术后参数、母婴结局、PBO 相关并发症和随访结局。此外,还进行了多变量逻辑回归分析,以确定 PBO 与大出血和子宫切除术风险之间的明确关联。
共有 285 例 PAS 患者符合纳入标准,其中 57 例 PAS 患者行 PBO(PBO 组),228 例行剖宫产术(CS)未行 PBO(对照组)。两组患者的基线特征存在差异,但 PBO 干预并未降低出血量、子宫切除术率和术后住院时间,反而延长了手术时间和增加了住院费用(均 P<0.05)。此外,两组患者术后并发症、新生儿结局和随访结局差异无统计学意义(均 P>0.05)。特别是,行 PBO 的患者术后更易发生静脉血栓形成(P=0.001)。然而,多变量逻辑回归分析显示,PBO 显著降低了大出血的风险(OR 0.289,95%CI:0.109-0.766,P=0.013)。PAS 分级和 MRI 伴有 S2 侵犯是影响大出血的显著危险因素(OR:6.232 和 OR:5.380,P<0.001)。
PBO 有可能降低行 CS 的 PAS 患者的大出血风险。然而,产科医生应注意 PBO 可能引起的并发症。此外,MRI 伴有 S2 侵犯和 PAS 分级有助于识别高危 PAS 患者,并可能从 PBO 中获益。简而言之,PBO 似乎是治疗 PAS 的一种有前途的选择,但需要进行精心设计的随机对照试验来令人信服地证明其益处并确定 PBO 的必要性。